About BioCheck Inc.
Founded in 1997 by Dr. John Chen, Ph.D., BioCheck specializes in the development of custom enzyme immunoassay kits, antibody purification and conjugation, contract manufacturing and assembly.
About Entia Biosciences, Inc.
Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.
For more information, please visit our web sites at http://www.entiabio.com/ or contact:
Chief Operating Officer
Entia Biosciences, Inc.
13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140
Phone: 503-334-3575, Email: firstname.lastname@example.org
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2012 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Honda M, Yamada Y, Tomonaga M, Ichinose H, Kamihira S.(2000). Correlation of urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study. Leuk. Res., 24(6):461-8.
Kern JK, Geier DA, Sykes LK, and Geier MR (2013). Evidence of neurodegeneration in autism spectrum disorder. Published online 2013 August 8. doi: 10.1186/2047-9158-2-17
Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2012). 8OHdG as a marker for Huntington disease progression. Neurobiol Dis.,46(3):625-34.
Mariani E., Polidori M. C., Cherubini A., Mecocci P. (2005). Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 827: 65–75.
Paul, B. & Snyder, S., (2009). The Unusual Amino Acid L-Ergothioneine is a Physiologic Cytoprotectant. Cell Death & Differentiation, pp. 1-7.
Wu LL, Chiou CC, Chang PY, Wu JT.(2004) Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta., 339(1-2):1-9.
SOURCE Entia Biosciences